EP3150256
Samsetning af mótefni gegn CD20 og hemli sem er sértækur fyrir PI3 kínasa
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
1.11.2013EP published:
15.7.2020EP application number:
16185090.4
EP translation filed:
18.8.2020Grant published:
15.9.2020EPO information:
European Patent Register
Max expiry date:
31.10.2033Expiry date:
31.10.2022
Title:
COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR
Timeline
Today
1.11.2013EP application
15.7.2020EP Publication
18.8.2020Translation submitted
15.9.2020Registration published
31.10.2022Expires
Owner
Name:
TG Therapeutics Inc.Address:
2 Gransevoort Street, 9th Floor, New York, NY 10014, US
Name:
Rhizen Pharmaceuticals S.A.Address:
Fritz Courvoisier 40, 2300 La Chaux de Fonds, CH
Name:
Laboratoire Français du Fractionnement et des BiotechnologiesAddress:
3, avenue des Tropiques, ZA Courtaboeuf,, 91940 Les Ulis, FR
Inventor
Name:
Weiss, MichaelAddress:
New York, NY 10014, US
Name:
Miskin, HariAddress:
New York, NY 10014, US
Name:
Sportelli, PeterAddress:
New York, NY 10014, US
Name:
Vakkalanka, Swaroop K.V.SAddress:
2300 La Chaux de Fonds, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
4595CH2012Date:
2.11.2012Country:
IN
Number:
201361771812 PDate:
2.3.2013Country:
US
Classification
Categories:
A61P 35/00, A61K 39/395, A61K 45/06, A61K 31/519, A61P 37/00, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 26.11.2020
Expires: 31.10.2021
Payer: The International Renewals Group Inc.
Number: 9
Paid: 13.10.2021
Expires: 31.10.2022
Payer: Örn Þór slf.